Board Change • Jun 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman Emeritus Stan Bergman was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • May 20
Insider recently bought €587k worth of stock On the 11th of May, William Daniel bought around 10k shares on-market at roughly €58.71 per share. This transaction increased William Daniel's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €6.1m more in shares than they bought in the last 12 months. Announcement • May 06
Henry Schein, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2026 Henry Schein, Inc. reaffirmed earnings guidance for the fiscal year 2026. For the period, the company expects 2026 total sales growth is unchanged and expected to be approximately 3% to 5% over 2025. Announcement • Apr 21
Henry Schein, Inc. to Report Q1, 2026 Results on May 05, 2026 Henry Schein, Inc. announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 05, 2026 Announcement • Apr 10
Henry Schein, Inc. Announces Board Retirements Henry Schein, Inc. announced its plan to reduce the size of its Board of Directors following its 2026 Annual Meeting of Stockholders on May 21, 2026. Stanley M. Bergman is to retire from the Board after 44 years as a director of Henry Schein. In addition, Joseph L. Herring, Robert J. Hombach, Scott Serota, and Bradley T. Sheares will not stand for reelection at the Annual Meeting of Stockholders. Accordingly, the Board of Directors has approved a reduction in size from fifteen to ten members, effective as of the end of the Annual Meeting. Announcement • Apr 09
Henry Schein, Inc., Annual General Meeting, May 21, 2026 Henry Schein, Inc., Annual General Meeting, May 21, 2026. Announcement • Jan 22
Henry Schein, Inc. to Report Q4, 2025 Results on Feb 24, 2026 Henry Schein, Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026 Announcement • Jan 14
Henry Schein, Inc. Announces the Appointment of Frederick M. Lowery to the Board of Directors, Effective March 2, 2026 On January 10, 2026, the Board of Directors of Henry Schein, Inc. (the Company) appointed Mr. Frederick Lowery, effective March 2, 2026 (the Effective Date), at which time he will join the Board of Directors. In connection with Mr. Lowery’s appointment, the Board expanded the size of the Board from 14 to 15 members and appointed Mr. Lowery to fill the resulting vacancy, in each case, effective as of the Effective Date. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc. in 2005 as head of operations for the Molecular BioProducts business of Fisher Scientific International. His experience growing distribution and owned product businesses – including manufacturing, R&D, marketing, and sales functions – closely aligns with Henry Schein’s business model, positioning him well to guide the Company’s next phase of growth and continued execution of its BOLD+1 strategic plan. Prior to joining Thermo Fisher, Mr. Lowery worked in leadership roles for Maytag Corporation and General Motors. He holds a master’s degree in manufacturing management from Kettering University (formerly General Motors Institute of Engineering and Management) and a bachelor’s degree in mechanical engineering from Tennessee Technological University. Announcement • Jan 13
Henry Schein, Inc. Appoints Frederick M. Lowery as Chief Executive Officer, Effective March 2, 2026 Henry Schein, Inc. announced the appointment of Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc. in 2005 as head of operations for the Molecular BioProducts business of Fisher Scientific International. His experience growing distribution and owned product businesses – including manufacturing, R&D, marketing, and sales functions – closely aligns with Henry Schein’s business model, positioning him well to guide the Company’s next phase of growth and continued execution of its BOLD+1 strategic plan. Prior to joining Thermo Fisher, Mr. Lowery worked in leadership roles for Maytag Corporation and General Motors. He holds a master’s degree in manufacturing management from Kettering University (formerly General Motors Institute of Engineering and Management) and a bachelor’s degree in mechanical engineering from Tennessee Technological University. Announcement • Nov 04
Henry Schein, Inc. Raises Earnings Guidance for the Year 2025 Henry Schein, Inc. raised earnings guidance for the year 2025. For the year, 2025 total sales growth is raised to be approximately 3% to 4% over 2024, previously 2% to 4% total sales growth. Announcement • Oct 21
Henry Schein, Inc. to Report Q3, 2025 Results on Nov 04, 2025 Henry Schein, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025 Announcement • Sep 11
Henry Schein, Inc. Announces Transition of James Breslawski from Senior Advisor Role, Effective from September 5, 2025 Henry Schein, Inc. announced that as previously disclosed on April 1, 2025, James Breslawski transitioned from the role of President of Henry Schein, Inc. (the “Company”) to Senior Advisor and member of the Company’s Executive Management Committee (“current role”). On September 5, 2025, Mr. Breslawski transitioned out of his current role. In connection with his transition, Mr. Breslawski will receive payments and benefits under the Company’s Executive Severance Plan. Recent Insider Transactions • Aug 12
Insider recently bought €577k worth of stock On the 7th of August, William Daniel bought around 10k shares on-market at roughly €57.68 per share. This transaction increased William Daniel's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €1.5m more in shares than they bought in the last 12 months. Reported Earnings • Aug 06
Second quarter 2025 earnings released: EPS: US$0.70 (vs US$0.81 in 2Q 2024) Second quarter 2025 results: EPS: US$0.70 (down from US$0.81 in 2Q 2024). Revenue: US$3.24b (up 3.3% from 2Q 2024). Net income: US$86.0m (down 17% from 2Q 2024). Profit margin: 2.7% (down from 3.3% in 2Q 2024). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Healthcare industry in Europe. New Risk • Aug 06
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 17% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Announcement • Aug 05
Henry Schein, Inc. Reaffirms Earnings Guidance for the Year 2025 Henry Schein, Inc. reaffirmed earnings guidance for the year 2025. For the year, total sales growth is unchanged and is expected to be approximately 2% to 4% over 2024. Announcement • Jul 22
Henry Schein, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Henry Schein, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 05, 2025 Announcement • Jul 15
Henry Schein, Inc. Announces Retirement of Stanley M. Bergman as Chief Executive Officer at the End of 2025 Henry Schein, Inc. announced that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. During Mr. Bergman’s tenure as CEO, Henry Schein’s revenue grew from $225 million in 1989 to almost $13 billion in 2024, representing an approximate compound annual growth rate of 17.5%, while the Company’s market capitalization grew from $290 million at the time of its IPO in 1995 to a current value of almost $9 billion1. Further, Henry Schein has delivered a non-GAAP EPS CAGR of 12.4% over this same period. Mr. Bergman concluded his letter by thanking many people who stood by his side during the journey, including senior management, the Board, the Schein family, and others. 
